RxDoctor Payments DataLook up a doctor →

Elizabeth Perkins, MD

Rheumatology · Hoover, ALNPI 1811105398

Payments from drug & device makers

$263,547in general payments, 2019–2025

Across 1,827 payments — averaging $144.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$77K
  • Lilly USA, LLC$48K
  • UCB, Inc.$42K
  • AbbVie$31K
  • Johnson & Johnson$18K
  • Pfizer$13K
  • plus $35K from 37 others

What the payments were for

  • Consulting fees$170,44265%
  • Speaking & faculty fees$31,36312%
  • Travel & lodging$23,7579%
  • Food & beverage$37,95314%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$263,547 in reported general payments places this provider in the 85th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama

Medicare billing

Part B allowed, 2024
$4,745,883
Medicare patients
292
Services billed
282,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib264$1,743,824
Humira(Cf) PenAdalimumab122$1,119,108
IlarisCanakinumab/Pf14$530,854
Skyrizi PenRisankizumab-Rzaa15$301,474
Xeljanz XrTofacitinib Citrate53$299,603
Orencia ClickjectAbatacept36$221,179
OtezlaApremilast35$185,123
Cimzia (2 Pack)Certolizumab Pegol21$159,802
Enbrel SureclickEtanercept17$127,140
XeljanzTofacitinib Citrate14$91,513
BenlystaBelimumab13$85,673
OrenciaAbatacept12$66,448
Hydroxychloroquine Sulfate583$45,171
MethotrexateMethotrexate Sodium464$20,231
Leflunomide105$12,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$30,879$1,743,824264 claims
NovartisIlaris$76,550$530,85414 claims
AmgenOtezla$12,342$185,12335 claims
UCB, Inc.Cimzia (2 Pack)$41,951$159,80221 claims
PfizerXeljanz$12,615$91,51314 claims
GSKBenlysta$1,456$85,67313 claims
E.r. Squibb & Sons, L.L.C.Orencia$5,945$66,44812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 rheumatology providers in Alabama.

Other rheumatology in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →